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Psoriasis, which is regarded as a T-cell-mediated chronic inflammatory skin disease, is
characterized by hyperproliferation and poor differentiation of epidermal keratinocytes. In
this study, we aimed to determine the in vivo effect of a potentially probiotic strain,
Lactobacillus pentosus GMNL-77, in imiquimod-induced epidermal hyperplasia and
psoriasis-like skin inflammation in BALB/c mice. Oral administration of L. pentosus GMNL-
77 significantly decreased erythematous scaling lesions. Real-time polymerase chain re-
action showed that treatment with L. pentosus GMNL-77 significantly decreased the mRNA
levels of proinflammatory cytokines, including tumor necrosis factor-alpha, interleukin
(IL)-6, and the IL-23/IL-17A axis-associated cytokines (IL-23, IL-17A/F, and IL-22) in the skin
of imiquimod-treated mice. In addition, we found that L. pentosus GMNL-77 decreased the
spleen weights of the imiquimod-treated group and reduced the numbers of IL-17- and IL-
22-producing CD4þ T cells in the spleen. In conclusion, the present study provides insight
into the potential use of L. pentosus GMNL-77 in the future treatment of psoriasis.
Copyright © 2016, Food and Drug Administration, Taiwan. Published by Elsevier Taiwan
LLC. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Science, National Pingtung University of Science and Technology, 1 Shuefu Road, Neipu,
tw (Y.-K. Chen).
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Psoriasis is a chronic inflammatory skin disorder character-
ized by epidermal keratinocyte hyperplasia and massive
leukocyte infiltration [1]. It affects approximately 2e3% of the
world population [2]. However, the underlying pathogenic
mechanisms of this condition have not been fully understood.
Recently, numerous studies have confirmed that T helper 17
(Th17) cells and the immune-derived cytokines these cells
produce, including interleukin (IL)-17, IL-22, and IL-23, were
detected in psoriatic skin lesions and serum that were
involved in and interacted as a network in the pathogenesis of
psoriasis [3e10].
Probiotics are defined as “living microorganisms that,
when administered in adequate amounts, confer health ben-
efits to the host” [11]. Most microorganisms identified to date
as probiotics belong to the genera Lactobacillus and Bifido-
bacterium, which have been extensively studied and
commonly used for centuries in humans and animals. Mod-
ulation of the immune system is one of the most plausible
mechanisms underlying the beneficial effects of probiotics on
human health. Probiotics have been found to enhance innate
immunity and modulate pathogen-induced inflammation via
toll-like receptor-regulated signaling pathways [12]. Recent
reports have shown that probiotic use is an effective preven-
tive and therapeutic strategy for different diseases ranging
from allergies to autoimmune diseases. Three interacting
factors, including an aberrant intestinal microflora, a “leaky”
intestinal mucosal barrier, and an altered intestinal immune
responsiveness, have been suggested as being able to create a
“perfect environment” for the development of autoimmune
diseases. In addition to autoimmune diseases, regulation of
the composition of intestinal microbiota by probiotics offers
the possibility of influencing the development of mucosal and
systemic immunity [13]. Probiotics have been reported to be
efficacious against cancers, infections, allergies, inflamma-
tory bowel diseases, and autoimmune diseases and it is
important to explain how such multifunctional activities are
generated. These findings can provide a theoretical basis for
understanding the multifunctional activities of specific pro-
biotics [14].
The actions of probiotics on the skin can be mediated by
the modulation of both the innate and the adaptive immune
responses in the host. Some probiotic strains display potent
immune-modulatory properties in the skin. Recently, the
ability of Lactobacillus paracasei CNCM-I 2116 (ST11) to modu-
late reactive skin-associated inflammatory mechanisms has
been evaluated. ST11 was able to abrogate vasodilation,
edema, mast cell degranulation, and tumor necrosis factor-
alpha (TNF-a) release induced by substance P compared with
controls. These results support a beneficial role of ST11 in key
biological processes associated with barrier function and skin
reactivity [15]. Oral administration of Lactobacillus casei can
reduce antigen-specific skin inflammation by controlling the
size of the CD8þ effector pool [16]. Oral administration of heat-
killed Lactobacillus sakei proBio65, which are isolated from
Kimchi, inhibited immunoglobulin E-mediated histamine andPlease cite this article in press as: Chen Y-H, et al., Lactobacillus pentosu
like mice, Journal of Food and Drug Analysis (2016), http://dx.doi.orgb-hexosaminidase release in NC/Nga mice. These results
suggest that dead L. sakei proBio65 has an inhibitory effect on
atopic dermatitis-like skin lesions; it is proposed to be a po-
tential treatment for allergies [17]. In addition, Lactobacillus
acidophilus cultured in a medium of taro waste hydrolysate
showed immune-modulatory effects in luciferase-based nu-
clear factor-kB and cyclooxygenase-2 systems [18]. Orally
administered L. casei DN-114 001 efficiently alleviates T-cell-
mediated skin inflammation without causing immune sup-
pression via mechanisms that include the control of CD8þ
effector T cells and the involvement of regulatory CD4þ T cells.
L. casei DN-114 001 may, thus, represent a probiotic of poten-
tial interest for the immunomodulation of T-cell-mediated
allergic skin diseases in humans [19].
Experimental data show that the imiquimod (IMQ)-
induced psoriasis model is highly correlated to human psori-
asis lesions with regard not only to the clinical and histolog-
ical characteristics, but also to the development of the lesions
via the IL-23/IL-17A axis [20]. This study was designed to
investigate the effect of Lactobacillus pentosusGMNL-77 (GMNL-
77), a potent probiotic strain that is commercially available as
a healthy food product in Taiwan, on an IMQ-induced psori-
asis-like mouse model. The effect of GMNL-77 on immune
responses was further investigated.2. Methods
2.1. Mice
Male BALB/c mice (6e8 weeks; 20e25 g) were purchased from
the National Laboratory Animal Center (Nangang District,
Taipei). The mice were housed at the facility of National
Chung Hsing University (South District, Taichung). All exper-
imental animals were used in this study according to a pro-
tocol approved by the Institutional Animal Care and Use
Committee of National Chung Hsing University.
2.2. Bacterial strain, media, and growth conditions
GMNL-77 was obtained from the culture collection of the
GenMont Biotech Incorporation (Shanhua District, Tainan).
GMNL-77 was statically grown in Man Rogosa Sharpe broth
(Difco Laboratories, Detroit, MI, USA) at 37C for 18 hours,
collected by centrifugation at 3000 g for 5 minutes to remove
the Man Rogosa Sharpe broth, and suspended in sterile water
at a concentration of approximately 2 109 colony-forming
units (CFU)/mL.
2.3. IMQ-induced psoriasis-like skin inflammation
protocol
After their back skin was shaved, the mice received a topical
application of 62.5 mg IMQ cream (Aldara; 3M Pharmaceuti-
cals, St Paul, MN, USA) daily for 6 consecutive days. For the
GMNL-77 treatment, the mice were fed orally with different
doses of GMNL-77 (5 107 CFU/0.2mL/d or 5 108 CFU/0.2mL/
d) or with the vehicle control (distilledwater) for 7 consecutives GMNL-77 inhibits skin lesions in imiquimod-induced psoriasis-
/10.1016/j.jfda.2016.06.003
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severity of inflammation of the back skin was evaluated using
a modified target lesion psoriasis severity scoring system.
Mice were monitored and graded daily with respect to back
redness (erythema) and the presence of scales (scaling), on a
scale from 0 (no alteration) to 4 (very distinct alteration).
2.4. Skin histology
On Experimental Day 6, the skin samples from the back
lesions of mice were fixed in 4% formaldehyde and
embedded in paraffin. Deparaffinized sections (6 mm) were
stained with hematoxylin and eosin to study their
microarchitecture.
2.5. Quantitative reverse transcriptase polymerase
chain reaction
At 72 hours after starting the experiment, total RNA was
extracted from the back skin lesions using the TRIzol (Invi-
trogen, Carlsbad, CA, USA), and complementary DNA was
generated using a Transcriptor First Strand cDNA Synthesis
Kit (Roche, West Sussex, UK). The relative express levels of
genes were assessed using SYBR Green Master Mix (Roche,
West Sussex, UK) with the following primers: TNF-a, F: 50-
GGCTGCCCCGACTACGT-30 and R: 50-CTCCTGTGGTATGAGA-
TAGCAAATC-3; IL-6, F: 50-TGCCATTGCACAACTCTTTTCT-30
and R: 50-TCGGAGGCTTAATTACACATGTTC-30; IL-23, F: 50-
GTATCCAGTGTGAAGATGGTTGTGA-30 and R: 50-CGGA
TCCTTTGCAAGCAGAA-30; IL-17A, F: 50-TTTTCAGCAAG-
GAATGTGGA-30and R: 50-TTCATTGTGGAGGGCAGAC-30; IL-
17F, F: 50-GAGGATAACACTGTGAGAGTTGAC-30 and R: 50-
GAGTTCATGGTGCTGTCTTCC-30; IL-22, F: 50-GAAGGCTGAAG-
GAGACAGTGAAA-30 and R: 50-GTTCCCCAATCGCCTTGA-30;
hypoxanthine guanine phosphoribosyl transferase 1 (HPRT), F:
50-GTTGGATAAGGCCAGACTTTGTTG-30 and R: 50-GATT-
CAACTTGCGCCATCTTAGGC-3; in Eco Real-Time PCR System
(Illumina, San Diego, CA, USA). The HPRT gene was used as a
reference to normalize the data. The relative expression level
of the gene in the experimental groupwas comparedwith that
of the water-treated mouse group.
2.6. Flow cytometry analysis
On Experimental Day 6, spleen cells of each group of mice
were weighed with an electronic balance and were then
extracted via mechanical disruption using 30 mm steel mesh
screens in a fresh Petri dish to prepare single-cell suspensions.
For intracellular detection of cytokines, 2 105 cells/well were
stimulated with plate-bound anti-CD3 mAb [clone 145-2C11
(BD Pharmingen, Oxford, UK); 5 mg/mL] and soluble anti-CD28
(1 mg/mL) for 24 hours. Golgistop solution (BD Biosciences, San
Diego, CA, USA) was put into the culture 4 hours before cell
harvesting. The cells were then stained with phycoerythrin-
conjugated antimouse CD4 (GK1.5; BioLegend), followed by
treatment with Cytofix/Cytoperm Plus Kit (BD Biosciences)
according to themanufacturer's instructions (BD Biosciences).
Cells were then stained intracellularly using the fluoresceinPlease cite this article in press as: Chen Y-H, et al., Lactobacillus pentosu
like mice, Journal of Food and Drug Analysis (2016), http://dx.doi.orgisothiocyanate (FITC)-conjugated mAbs specific to murine IL-
17A (TC11-18H10.1) and IL-22 (Poly5164), purchased from
BioLegend. The stained cells were acquired on a BD Accuri C5
cytometer Cat. No. 657214 (BD Biosciences, San Jose, CA, USA)
and analyzed with BD Accuri C6 software, version 1.0264.21.2.7. Statistical analysis
The data were expressed as mean± standard deviation. Sta-
tistical significance between groups was compared using the
ManneWhitney U test compared with water-treated IMQ
control. All the statistical analyses were performed using
GraphPad Prism software package, version 5.0 (GraphPad
Software, San Diego, CA, USA). Significance was assigned at
p< 0.05.3. Results
3.1. GMNL-77 alleviates skin lesions in IMQ-induced
psoriasis-like mice erythema (0.80± 0.40, p< 0.05) and
scaling (0.75 ± 0.33, p< 0.05)
As shown in Figures 1A and 1B, mice developed apparent
psoriasis-like lesions, including erythema and scaling of the
lesion skin, after treatment with IMQ for 6 consecutive days.
Meanwhile, mice fed 5 108 CFU/d of GMNL-77 showed
significantly reduced lesions in the IMQ-treated group
(p< 0.05) (Figures 1A and 1B). The erythema and scaling scores
of the GMNL-77 (5 108 CFU/d) group were 2.13- and 2.26-fold
less than the IMQ group at the end of the experiment. To
further analyze the effects of GMNL-77, histological (hema-
toxylin and eosin) staining was also carried out on the skin
lesions in mice on Day 6. The results showed that the
epidermal thickness significantly increased in the IMQ-
treated skin as a result of hyperproliferation of keratino-
cytes. However, a high dose of GMNL-77 (5 108 CFU/d)
reduced the IMQ treatment-induced thickness of the
epidermal tissue.3.2. GMNL-77 suppresses inflammatory cytokines in the
skin lesions of IMQ-treated mice
Recently, cytokines have also been found to be involved in the
induction of IMQ-induced psoriasis-like inflammation
[3,20e24]. Cytokines play important physiological and patho-
logical roles in many diseases [25]. Therefore, to further
explore whether GMNL-77 inhibits proinflammatory and
Th17-associated cytokine production, we analyzed these
psoriasis-related cytokine profiles in the skin lesions using
quantitative reverse transcriptase polymerase chain reaction
analysis. As shown in Figure 2, the levels of TNF-a (6.50± 2.38,
p< 0.05), IL-6 (0.81± 0.59, p< 0.05), IL-23 (1.77± 0.78, p< 0.05),
IL-17A (1.13± 0.61, p< 0.05), IL-17F (2.93± 1.67, p< 0.05), and IL-
22 (4.55± 1.11, p< 0.05) were significantly reduced when mice
were treated with a high dose of GMNL-77 (5 108 CFU/d).s GMNL-77 inhibits skin lesions in imiquimod-induced psoriasis-
/10.1016/j.jfda.2016.06.003
Figure 1 e GMNL-77 reduced psoriasis-like skin inflammation. (A) Phonotypical presentation of the effects of oral
administration of GMNL-77 on IMQ-induced psoriasis-like skin lesions after 6 days of treatment. (B) Erythema and
scaling of back skin scored daily on a scale from 0 to 4. Symbols represent mean score± SD of six mice per group. Data
shown are representative of three experiments. (C) Representative photomicrographs of hematoxylin and eosin-stained
section of back skin tissue of the experimental mice. * p< 0.05 (ManneWhitney U test) versus IMQ/water control group.
GMNL-77 ¼ L. pentosus GMNL-77; IMQ ¼ imiquimod; SD ¼ standard deviation.
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Figure 2 e GMNL-77 reduced mRNA levels of skin inflammatory cytokines and IL-23/IL-17-associated cytokines in the back
skin induced by IMQ. Skin was excised from different treatment groups at 72 hours, and RNA was extracted to analyze
mRNA expression of TNF-a, IL-6, IL-23, IL-17A, IL-17F, and IL-22 by real-time RT-PCR. The HPRT gene was used as a
reference to normalize the data. The relative expression level of the gene in the experimental groupwas compared with that
of the water-treated mouse group. Data on the graph represents the mean± SD, with six mice per group. Data shown are
representative of three experiments. * p< 0.05 (ManneWhitney U test) versus IMQ/water control group. GMNL-77 ¼ L.
pentosus GMNL-77; HPRT ¼ hypoxanthine guanine phosphoribosyl transferase 1; IL ¼ interleukin; IMQ ¼ imiquimod;
ns ¼ not significant; RT-PCR ¼ reverse transcriptase polymerase chain reaction; SD ¼ standard deviation; TNF-a ¼ tumor
necrosis factor-alpha.
j o u rn a l o f f o o d and d r u g a n a l y s i s x x x ( 2 0 1 6 ) 1e8 53.3. GMNL-77 reduces the number of Th17/Th22 T cells
in the spleen of IMQ-treated mice
To further determine whether orally administered L. pentosus
can affect systemic immune responses, we initially examined
the spleen weights on Day 6 after IMQ treatment (Figure 3).
IMQ was previously found to induce splenomegaly through
systemic effects [20]. In this study, our data identified a
consistently significant spleen enlargement following 6 days
of IMQ treatment in mice. However, the average spleen
weights of the mice in the IMQ-treated-group were reduced
after these mice were fed with 5 108 CFU/d of GMNL-77
(399.8± 81.8 vs. 176.5± 43.0, p< 0.05) (Figure 4A).
By contrast, in several different chronic inflammatory
conditions including psoriasis, IL-17 and IL-22 are secreted by
CD4þ [20,26]. Therefore, we determined the effect of GMNL-77
on IL-17 and IL-22 production by CD4þ T cells in the spleen.
Splenic cells were activated ex vivo by anti-CD3þ plus anti-
CD28 Ab, stained intracellularly for IL-17 or IL-22 in gatedPlease cite this article in press as: Chen Y-H, et al., Lactobacillus pentosu
like mice, Journal of Food and Drug Analysis (2016), http://dx.doi.orgCD4þ T cells and analyzed using flow cytometry. As shown in
Figure 4B, the numbers of IL-17A-producing CD4þ T cells
(Th17) and IL-22-producing CD4þ T cells (Th22) were increased
following IMQ treatment. However, the percentages of Th17
and Th22 cells in the spleens of the GMNL-77 (5 108 CFU/d)-
fed group were significantly lower than those of the IMQ-
treated control group (Figure 4B). These results imply that
GMNL-77 reduces the differentiation of CD4þ T cells to inhibit
the systemic inflammatory response following IMQ
treatment.4. Discussion
IMQ, a kind of immunomodulating drug, was first approved by
FDA for the topical treatment of external genital and perianal
warts in 1997, and now is also used to treat superficial basal
cell carcinoma and actinic keratosis [27e29]. However, IMQ
may cause certain side effects related to inflammation, suchs GMNL-77 inhibits skin lesions in imiquimod-induced psoriasis-
/10.1016/j.jfda.2016.06.003
Figure 3 e GMNL-77 reduced the size and weight of the spleen induced by IMQ. (A) Mice were sacrificed on Day 6, size of
spleens with comparison in representative images direct-viewing. (B) The spleens were weighed when the mice were
sacrificed. The bar graphs represent the mean± SD, with six mice per group. Data shown are representative of three
experiments. * p< 0.05 (ManneWhitney U test) versus IMQ/water control group. GMNL-77 ¼ L. pentosus GMNL-77;
IMQ ¼ imiquimod; SD ¼ standard deviation.
j o u r n a l o f f o o d and d r u g an a l y s i s x x x ( 2 0 1 6 ) 1e86as blisters, burning sensation, skin redness, skin flaking, or
scaling. It has been reported that IMQ-induced skin inflam-
mation of mice can be utilized as a model of human psoriatic
lesions that exhibit similar phenotypic and histological char-
acteristics, including erythema, epidermal thickening,
scaling, and neoangiogenesis, as well as the inflammatory
infiltrates of T cells, neutrophils, and dendritic cells [30]. In the
present study, we investigated the effect of L. pentosus on skin
lesions in IMQ-induced psoriasis-like mice model.
L. pentosus is a versatile lactic acid bacterium found in
various environmental niches and in the gastrointestinal
tract. It is widely used in the production of fermented foods,
such as milk, breads, and vegetables, especially table olives
[31]. Specific L. pentosus strains have been shown to elicit
probiotic effects, including modulation of the intestinal
microbiota [32], inhibition of bacterial and viral pathogens
[33], and regulation of the host immune response [34]. In this
study, GMNL-77 appears to inhibit IMQ-induced psoriasis-like
inflammation in the skin of IMQ-treated mice based on the
following roles of GMNL-77: (1) decreased skin erythema and
scaling; (2) inhibited hyperplastic basal suprabasal keratino-
cytes; (3) suppressed mRNA expression of proinflammatory
cytokines, including TNF-a, IL-6, and the IL-23eIL-17 cytokine
axis (IL-23, IL-17A/F, IL-22) in skin lesions; (4) decreased the
spleen weights; and (v) reduced the numbers of IL-17/IL-22-
producing CD4þ T cells in the spleen of the IMQ-treated mice.
For the systemic action of IMQ, several weeks of topical
treatment leads to psoriasis lesions, a severe side effect, not
only at the site of application, but also at inaccessible sites
[28,29]. The IMQ-induced skin inflammation model in mice
helps illustrate this appearance. We found significant
splenomegaly in IMQ-treated mice at the end of thePlease cite this article in press as: Chen Y-H, et al., Lactobacillus pentosu
like mice, Journal of Food and Drug Analysis (2016), http://dx.doi.orgexperiment, and the spleen weight increased approximately
threefold when compared with the naive group. The spleen is
the largest immune organ reflecting systemic immune status
in the human body and plays an important role in anti-
infection and anticancer activities since it possesses various
immunocompetent cytokines [35]. It is suggested that the
increased spleenmass observed in the IMQ-induced psoriasis-
likemice is due to a large increase in the number of cells in the
spleen andmay be a sign of increasing the immunoreaction in
the body [30]. Enhancement of Th17/Th22 T cells in the spleen
of IMQ-treated mice was confirmed in the present study. Oral
administration of GMNL-77 (5 108 CFU/d) significantly
reduced spleen mass in IMQ-treated mice, which suggests
that GMNL-77 can decrease the number of Th17/Th22 T cells
of the spleen and alleviate the inflammatory response.
Recent studies have demonstrated that IL-17- and IL-22-
producing Th17 and Th22 cells serve as models for analyzing
the pathogenic mechanisms associated with psoriasis-like
dermatitis [21,22,36,37]. First, the results of the present study
show that GMNL-77 can decrease the percentage of IL-17A-
and IL-22-producing CD4þ T cells in the IMQ-treated mice
(Figure 4). Although themechanism for GMNL-77-suppressing
T-cell activity in vivo is unclear, we propose the following two
possibilities: (1) GMNL-77 may decrease the activity of the
intestinal antigen-presenting cells, such as the CD103þ den-
dritic cells, which have been shown to play a critical role in
modulating Tregs in the gastrointestinal tract, thus affecting
cell proliferation or differentiation; and (2) GMNL-77 has a
direct effect on the molecular mechanisms of the differenti-
ation or proliferation of T cells.
In summary, we demonstrate that oral administration of
GMNL-77 is an effective remedy for treating psoriasis in as GMNL-77 inhibits skin lesions in imiquimod-induced psoriasis-
/10.1016/j.jfda.2016.06.003
Figure 4 e GMNL-77 decreased the numbers of Th17 and Th22 cells of the mice spleen induced by IMQ treatment. Mice were
sacrificed on Day 6, spleen cells were isolated, and in vitro stimulated for 24 hours by plate-bound anti-CD3 and anti-CD28
Ab. Data from flow cytometry were analyzed for the number of IL-17AþCD4þTh17 and IL-22þCD4þTh22 cells. (A) The
dot plots show data from one representative mouse of each group. (B) The bar graphs represent themean± SDwith six mice
per group. Data shown are representative of three experiments. * p< 0.05 (ManneWhitney U test) versus IMQ/water control
group. GMNL-77 ¼ L. pentosus GMNL-77; IL ¼ interleukin; IMQ ¼ imiquimod; SD ¼ standard deviation; Th ¼ T helper cells.
j o u rn a l o f f o o d and d r u g a n a l y s i s x x x ( 2 0 1 6 ) 1e8 7mouse model. These effects were the result of inhibiting the
differentiation and proliferation of keratinocytes reducing the
levels of skin inflammatory cytokines and the differentiation
of IL-17/IL-22-producing CD4þ T cells in the spleen. Data ob-
tained from these studies are encouraging; however, the
molecular and cellular mechanisms responsible for the mul-
tiple effects of GMNL-77, such as anti-inflammatory factor
expression and the search for a new and efficient element to
dampen the inflammation process, require further
investigation.Conflicts of interest
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